August 2026 Research Update

Across these papers, researchers focused on tests that might help distinguish multiple system atrophy (MSA) from Parkinsons disease earlier and more reliably. The clearest signal came from a large multicenter blood study, while other approaches (skin biopsy, immune-cell gene patterns, and heart imaging) were smaller or more exploratory and need more confirmation. Overall, results suggest that combining different types of information (blood markers, tissue markers, and organ-specific testing) may help explain why a single test does not fit everyone. [1] [2] [3] [4]

In a multicentre diagnostic study of 2408 people, a blood marker of nerve-cell damage called neurofilament light chain separated MSA from Parkinsons disease well, including in an early-stage subgroup (area under the curve 0.943). Adding other blood markers (GFAP, total tau, and p-tau217) only slightly changed performance, suggesting neurofilament light chain carried most of the useful information in that dataset. [1]

In a 12-month prospective cohort of 17 people with early probable MSA, phosphorylated alpha-synuclein deposits in skin nerves increased over time and were linked to measures of orthostatic low blood pressure and higher autonomic symptom scores. Some people who were negative on a separate seed amplification test still showed alpha-synuclein in skin, which suggests skin biopsy might sometimes provide different information than fluid-based testing. The study did not find a clear link between skin deposits and overall disease severity in that follow-up period. [2]

A translational study comparing Parkinsons disease with the parkinsonian type of MSA (MSA-P) reported that common blood inflammation ratios did not separate early cases well, but more detailed testing showed group differences. It found distinct gene-activity patterns in certain immune cells (monocytes) and different locations of alpha-synuclein signal inside red blood cells (more membrane-associated in MSA-P and more cytoplasmic in Parkinsons disease for one measured form), suggesting a possible multi-part blood-based approach that still needs larger validation. [3]

In a diagnostic accuracy study of 103 people with parkinsonism, a heart scan measuring cardiac sympathetic nerve function (mIBG scintigraphy) helped distinguish idiopathic Parkinsons disease from other parkinsonisms, and it had moderate separation between idiopathic Parkinsons disease and MSA (area under the curve 0.829 using a late ratio measure). This supports the idea that heart-nerve involvement can differ between conditions, but the test is not perfectly separating on its own. [4]

For patients and caregivers, this group of studies mainly adds context about why diagnosis can be complex and why clinicians often look at several kinds of evidence. The strongest near-term message is that a simple blood test (neurofilament light chain) showed high accuracy for separating early MSA from Parkinsons disease in a large study, while skin biopsy, detailed blood-cell profiling, and heart scans may provide extra pieces of information but remain less certain or less widely validated. What is still uncertain is how these tests perform across different clinics, across MSA subtypes, and over time in the same person, and how best to combine them into an approach that is reliable in everyday care. [1] [2] [3] [4]

These studies looked beyond standard exams to see whether brain imaging patterns or genetic-related clinical features can help distinguish MSA from similar conditions or separate MSA subtypes. Two imaging studies reported disease-pattern differences on specialized MRI methods, but both were exploratory (one retrospective and one small cross-sectional). A separate moderate-strength cohort comparison suggested that certain symptoms may point toward an inherited ataxia that can resemble the cerebellar form of MSA. [5] [6] [7]

In a retrospective single-center study using quantitative susceptibility mapping (an MRI method sensitive to iron), people with Parkinsons disease, MSA-P, and progressive supranuclear palsy all showed increased signal in areas such as the substantia nigra and basal ganglia compared with healthy controls. MSA-P showed higher signal than Parkinsons disease in several regions including the substantia nigra, putamen, pallidum, parts of the frontal lobe, and the dentate nucleus, and an internally validated machine-learning model distinguished Parkinsons disease from MSA-P with an area under the curve of 0.800. These results suggest pattern-based imaging may help, but the work is exploratory and from one center. [5]

A small cross-sectional imaging study using phosphorus magnetic resonance spectroscopy (31P-MRSI) reported that the cerebellar subtype of MSA (MSA-C) had lower ratios of high-energy phosphate metabolites in the cerebellum than healthy controls, while the parkinsonian subtype (MSA-P) looked similar to controls. The study did not find consistent group differences in these metabolite ratios in the basal ganglia, and the authors noted limitations such as sample size and spatial resolution, meaning this is not ready as a diagnostic test. [6]

In a French prospective cohort of late-onset cerebellar ataxia, researchers compared 20 people with RFC1-related ataxia to 65 people with MSA-C and found the RFC1 group tended to have earlier onset, slower progression, and much longer median survival (more than 20 years). Sensory impairment and chronic cough stood out as differentiating features between RFC1-related ataxia and MSA-C in this cohort, highlighting that some MSA-like presentations may have a different underlying cause. [7]

For patients, these papers mainly help explain the range of tools researchers are testing to better sort out conditions that can resemble MSA, especially when cerebellar symptoms are prominent. Specialized MRI methods may capture different brain patterns in MSA-P or MSA-C, but they are still mainly research tools and may not be available or standardized across centers. The cohort comparison with RFC1-related ataxia underscores that certain symptom clusters (like sensory changes or long-standing cough) can matter when clinicians are considering look-alike diagnoses, but the exact role of routine genetic or imaging testing remains uncertain and depends on further validation. [5] [6] [7]

Two cohort studies pointed in the same direction: measurable markers collected during routine care (brain MRI patterns, nutrition and weight change, and baseline symptom severity) helped identify people more likely to decline faster or have shorter survival without tracheostomy. The evidence comes from one prospective study focused on progression and one retrospective study focused on survival, so results describe patterns in groups rather than certainties for an individual. [8] [9]

In a 2-year prospective study of early-stage multiple system atrophy (MSA), people who were "MRI-positive" using MSA-specific MRI markers worsened faster on the Unified MSA Rating Scale (UMSARS) total score than those who were "MRI-negative". This faster progression was especially clear in the MSA-P subgroup (MSA with parkinsonism features), and MRI-positive status still predicted greater worsening after accounting for age, sex, and disease duration. [8]

In a retrospective cohort, poorer nutritional status and faster weight-related change were linked to shorter tracheostomy-free survival (time until death or tracheostomy). Lower prognostic nutritional index (PNI), greater annual body mass index decline, and a higher baseline score on the UMSARS swallowing item each independently predicted shorter survival, with mean survival reported as 3.3 years after diagnosis in this dataset. [9]

For patients and caregivers, these studies suggest that information already collected in many clinics (brain MRI features, symptom rating scales, and trends in weight/nutrition measures) may help researchers and clinicians describe expected pace of change in groups of people with MSA. This is most useful right now as background for understanding prognosis and for designing research studies that need to compare people at similar risk levels. It remains uncertain how well any single marker predicts what will happen for one person, and the studies did not test whether changing these markers changes outcomes. [8] [9]

Across this paper, the main message is that testing for autonomic blood pressure problems can vary a lot unless clinics use a consistent setup, monitoring approach, and safety steps. The authors lay out a standardized head-up tilt test method intended to improve how reliably blood pressure changes are captured in neurodegenerative conditions such as multiple system atrophy. [10]

The protocol emphasizes practical details that can change results, such as controlling the testing environment and using continuous, noninvasive beat-to-beat blood pressure monitoring during the tilt. It also specifies key parts of the tilt itself (how the tilt is performed and observed) so measurements are more comparable across visits and across different centers. [10]

Safety considerations are included, recognizing that people with autonomic blood pressure instability may feel faint or unwell during testing. The goal is to support both clinical care and research by using the same core approach when evaluating cardiovascular autonomic dysfunction. [10]

For patients and caregivers, this is mainly background and process-focused research: it does not test a new treatment or report symptom outcomes, but it explains how clinics can measure blood pressure drops in a more standardized way. Over time, more consistent testing could make it easier to compare results across appointments or studies, but it is still uncertain how much this alone changes day-to-day management because clinical outcome data were not reported. [10]

These papers point to several possible molecular contributors to multiple system atrophy (MSA): changes in a brain-related gene (BIN1), rare variants affecting lysosome function (MCOLN1), and differences in certain metals measured in blood. The overall message is that signals are emerging, but most are early and need confirmation in larger, independent groups before they can be considered reliable markers of risk or disease biology. [11] [12] [13]

In a genetic association study that included brain tissue, a long stretch of AGG repeats in the BIN1 gene was more common in pathologically confirmed MSA brains than in brain controls. BIN1 protein also showed more clumping (aggregation) in MSA brain tissue, and the amount of insoluble BIN1 was higher in MSA brains even when the repeat expansion was not present, suggesting BIN1 changes may be part of MSA biology rather than a single-gene explanation for all cases. [11]

A separate report described two individual patients with alpha-synuclein-related conditions (one with MSA and one with early-onset Parkinson's disease) who carried different MCOLN1 gene variants. Lab tests in cells suggested these variants reduced the function of TRPML1, a lysosome channel involved in cellular waste handling, but because this is based on two people it cannot show how common or important these variants are in MSA overall. [12]

In a small case-control study of blood samples, people with clinically established MSA had higher aluminum and copper and lower iron and zinc than healthy controls. One composite score (Metal Burden Index) looked higher in MSA, but it was largely driven by aluminum, and the study did not find clear links between these blood levels and how severe symptoms were at the time of testing; the authors emphasized the need for independent validation and careful control of confounders. [13]

For patients and caregivers, these results mainly add background about what researchers are testing as possible contributors to MSA, rather than providing information that is ready for personal risk prediction or diagnosis. The BIN1 repeat result was strongest in confirmed brain samples but was less clear in the clinical (blood) comparison, the MCOLN1 work is based on single-patient observations plus laboratory testing, and the blood metal patterns come from one small, cross-sectional study without disease-control groups. Key uncertainties include how often these signals occur across different MSA populations, whether they relate to cause versus downstream effects of illness, and whether any could become dependable tests after larger studies.

Across these papers, researchers tested two ways of directly interfering with alpha-synuclein: engineered small antibodies designed to bind alpha-synuclein, and a short peptide based on a natural helper protein that sticks to alpha-synuclein. Both approaches reduced harmful alpha-synuclein changes in lab settings, but the evidence is preclinical, so it cannot yet tell us whether these strategies will help symptoms or slow disease in people. [14] [15]

In a fruit fly model of synucleinopathy (an animal model where alpha-synuclein causes nerve cell problems), one single-domain antibody called 2H1 was the most consistently effective across several measures. It lowered a disease-linked form of alpha-synuclein (phosphorylated alpha-synuclein), helped preserve dopamine-producing nerve cells, improved movement in climbing tests, improved measures of mitochondrial function, and extended lifespan in some fly experiments. [14]

The same study suggested that where an antibody binds on alpha-synuclein may matter: 2H1 targeted an aggregation-prone hydrophobic region of alpha-synuclein (amino acids 61-95) and showed reliable interaction with alpha-synuclein inside the animal model. Results also varied by sex in the flies, and not every antibody helped every outcome, highlighting that these are early, model-dependent results. [14]

A separate biochemical and structural study mapped a direct contact between alpha-synuclein and DJ-1, a chaperone protein that can help other proteins fold or stay stable. In test-tube experiments, DJ-1 reduced alpha-synuclein fibril formation, and a short DJ-1-derived peptide (positions 173-180) also reduced alpha-synuclein aggregation in lab assays. [15]

For patients and caregivers, these studies mainly matter as background research: they show concrete, measurable ways scientists are trying to block alpha-synuclein clumping or reduce harmful forms of alpha-synuclein, which is central to multiple system atrophy biology. What remains uncertain is whether these approaches can be delivered safely to the right brain cells, work in mammal models that better mirror human disease, and eventually translate into meaningful changes in daily function for people.

Across these lab and animal studies, alpha-synuclein (a brain protein that can misfold and clump) behaved differently depending on where it came from and how it was formed. Overall, the results point to MSA having alpha-synuclein that is particularly good at spreading harmful clumps into oligodendroglia (support cells that help nerve wiring), while differences between MSA subtypes may be driven more by which brain regions are affected than by different alpha-synuclein strains. [16] [17]

When researchers amplified alpha-synuclein from MSA and Parkinsons disease (PD) brains and tested it in nerve cell cultures and mice, the MSA-derived material caused stronger buildup of a modified form called phosphorylated alpha-synuclein. It also produced more alpha-synuclein clumps in oligodendroglia than material amplified from PD brains, which fits with MSA being notable for oligodendroglial involvement. [16]

In a separate study using brain tissue from people with the cerebellar-predominant form of MSA (MSA-C) and the parkinsonian-predominant form (MSA-P), researchers did not find meaningful differences in alpha-synuclein shape fingerprints, seeding behavior in seed amplification assays, or the pace and pattern of disease after transfer into a transgenic mouse model. This supports the idea that MSA-C and MSA-P can share the same basic alpha-synuclein strain, with clinical differences possibly reflecting where in the brain the process becomes established. [17]

This group of studies is background research that helps explain why MSA can look different from Parkinsons disease and why MSA often involves support cells in the brain. It does not change diagnosis or care right now, but it may guide future research toward tests that detect MSA-type alpha-synuclein and toward therapies aimed at blocking spread into oligodendroglia. Important uncertainties remain, including how well mouse and lab models capture the full human disease and whether smaller subtype differences exist that current assays cannot detect. [16] [17]

Across these studies, unusual lab results and everyday symptoms were examined as possible clues about brain health, two of them in people with parkinsonism and one in a broad health-record population. The overall message was mixed: some tests that seem specific can be misleading, while a large general-population study, not in multiple system atrophy, linked diagnosed voice disorders to later cognitive decline. Evidence ranged from one detailed case report to large health record analyses, so certainty varies by finding. [18] [19] [20]

One case report described a 41-year-old woman with rapidly progressing parkinsonism whose spinal fluid showed low breakdown products of dopamine and serotonin, plus low tetrahydrobiopterin, which suggested a problem making neurotransmitters. She was treated for that suspected condition, but continued to decline, and autopsy later showed multiple system atrophy, parkinsonian subtype (MSA-P), along with early amyloid-beta buildup in the brain. The authors cautioned that multiple system atrophy itself can lower these spinal fluid chemicals and may mimic a neurotransmitter synthesis disorder in adults. [18]

A retrospective cross-sectional study of 329 people compared Parkinsons disease, multiple system atrophy, and progressive supranuclear palsy (PSP) using the triglyceride-glucose (TyG) index, a blood-based marker related to insulin resistance. TyG and lipid levels were similar across the groups, meaning this index did not distinguish Parkinsons disease from multiple system atrophy or PSP in this dataset. PSP had lower fasting glucose and worse cognitive scores than the other groups, but the study suggested other metabolic measures may need testing in future work. [19]

In a large electronic health record study of 833,417 people, diagnosed voice disorders were linked to a higher chance of later cognitive decline compared with matched controls. The highest risk was seen when voice disorders and hearing loss occurred together, higher than either condition alone. This study was not focused on multiple system atrophy specifically, but it adds to the broader picture that communication-related diagnoses can track with future cognitive outcomes. [20]

For patients and caregivers, these papers mainly provide context about how complex symptom-and-test interpretation can be in parkinsonism. The single-patient report suggests that some spinal fluid results that look like a rare neurotransmitter-making disorder can also occur in multiple system atrophy, which may complicate early workups. The metabolic study suggests a simple blood index (TyG) may not help separate multiple system atrophy from Parkinsons disease, while the large health record study suggests voice disorders, especially alongside hearing loss, can be a marker linked to future cognitive decline, though it does not prove cause and effect and was not specific to multiple system atrophy.